• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

consulting

  1. SmileDirectClub posts wider loss in Q1

    SmileDirectClub, Inc. (SDC) reported a wider loss in the first quarter of 2020 due to higher costs and expenses. However, the top-line increased by 11% year-over-year driven by an increase in unique aligner shipments and higher average aligner gross sales price. Take a look at the visual...
  2. Consulting’ for pharma companies: is it worth the time of day?

    As an senior academic +25 years service, I have seen a dive to’ the bottom when’ we are invited to provide consulting services and’ ad board service to the’ pharmaceutical sectors’. They are paying less good rates, flights on cheapest enc class seats, on bugdet airlines for senior PhD or more...